Chemed: Empire of Care - [Business Breakdowns, EP.215]

Episode Summary

Executive Summary: The episode examines KemEd, a highly unusual public company pairing emergency plumbing (Roto-Rooter) with hospice care (VITAS). Guest Chad Garcia argues the real engine is disciplined capital allocation: both businesses are fragmented, asset-light, cash-generative, and resilient, allowing KemEd to compound EPS and repurchase stock for decades while maintaining a net cash balance sheet.

Main Topics: KemEd’s unusual corporate history and structure (Priority: 5/5): KemEd evolved from a WR Grace spin-off into a holding company for two very different operating businesses: Roto-Rooter and VITAS. The discussion traces the major transactions that created the current portfolio and explains why the company is effectively a capital-allocation vehicle. Capital allocation as the core business model (Priority: 5/5): Management repeatedly emphasizes that KemEd exists to grow free cash flow per share rather than optimize any single end market. The company uses cash for buybacks, selective acquisitions, modest dividends, and opportunistic franchise repurchases, producing long-run EPS compounding well above revenue growth. Roto-Rooter’s brand, franchise model, and competitive position (Priority: 4/5): Roto-Rooter is framed as the gold standard in emergency plumbing, benefiting from strong brand recognition, same-day urgent service demand, and scale advantages in marketing, back office, and SEO. The business mixes company branches, royalty-based contractors, and low-cost franchise fees. VITAS hospice care and reimbursement-driven economics (Priority: 5/5): VITAS provides end-of-life hospice and palliative care, mostly in patients’ homes. The business benefits from demographic tailwinds, government reimbursement, and portfolio management across patient sources and geographies to navigate Medicare caps and acuity limits. Fragmentation, scale, and defensibility in both industries (Priority: 4/5): Both businesses are highly fragmented and people-intensive but require relatively little capital. Scale helps KemEd outperform mom-and-pop operators and smaller competitors, while VITAS also benefits from operating in denser markets with better utilization and higher margins. Management quality, culture, and succession (Priority: 3/5): The company’s culture is judged by actions: treating patients and employees well, acting as a credible industry advocate, and buying back stock when undervalued. Succession concerns are mild but real given CEO Kevin McNamara’s age and the prominence of VITAS leadership.

Key Arguments: KemEd’s best feature is not the mix of businesses but the discipline to grow free cash flow per share and redeploy it rationally. Roto-Rooter is defensible because emergency plumbing is urgent and price-insensitive; brand and SEO matter, and scale beats local competitors. VITAS has a structural tailwind because deaths in the U.S. are rising, and hospice care is often cheaper and better for Medicare than repeated hospital interventions. Both businesses are asset-light, cash-generative, and fragmented, which makes them ideal for compounding capital over long periods. KemEd’s long-term EPS growth exceeds revenue growth because margins improved and buybacks steadily reduced share count. The company’s willingness to act ethically, even when it reduces near-term profit, supports trust with regulators, employees, and customers. KemEd can hold, sell, spin, or buy more businesses depending on where intrinsic value and holdco discounts stand; it is not constrained by a fixed conglomerate identity.

Data Points: EPS CAGR since 2003: 21% - Described as the result of strong capital allocation and buybacks across KemEd. Market capitalization: $8.5 billion - Approximate size of KemEd mentioned early in the discussion. Net cash balance sheet: Net cash - KemEd is described as having a conservative balance sheet. KemEd revenue: ~$1.5 billion - Enterprise-level revenue estimate cited during the breakdown. KemEd EBITDA: $500 million to $600 million - Approximate combined EBITDA of the two businesses. Roto-Rooter revenue growth: ~6% annually - Historically driven by population growth, new households, and inflation. Roto-Rooter EBITDA margin: ~25% - Stated typical margin profile for the plumbing business. Roto-Rooter earnings growth: ~12% annually - Growth enhanced by margin expansion. Roto-Rooter share of earnings: 30% to 35% - Current estimate of Roto-Rooter’s contribution to total earnings. Emergency/same-day share of Roto-Rooter calls: 70% to 75% - Most service calls are urgent or same-day, supporting pricing power. Roto-Rooter market share: 2% to 3% of plumbing; 15% of drain cleaning - Shows fragmentation and niche dominance within drain cleaning. Roto-Rooter franchises: ~360 franchises - Number of franchise locations referenced in the discussion. Independent contractor royalty fee: 28% - Fee paid by contractor partners for marketing and back-office support. VITAS revenue: ~$1.6 billion - Approximate annual revenue for the hospice business. VITAS EBITDA margin: 15% to 22% - Margin range cited for the hospice business. VITAS revenue growth: ~6% annually - Historical organic growth rate. VITAS earnings growth: ~12% annually - Growth aided by margin expansion. VITAS market share: ~12% of hospice market - Estimated share in a highly fragmented industry. Deaths per year before COVID: ~2.5 million - Used to frame long-term demand growth for hospice care. Current annual deaths: ~3 million - Demographic basis for increasing hospice demand. Projected annual deaths in the 2040s: Just under 4.5 million - Long-term tailwind for hospice utilization. Government share of hospice bills: 96% - Hospice reimbursement is overwhelmingly government-funded. Medicare share of hospice reimbursement: 93% of government funding - Hospice care is primarily paid through Medicare. Medicare spending share in last year of life: 30% - Explains why hospice can save money for the system. Hospice cap: $34,560 - Maximum total amount the government will pay per patient. High-acuity care cap: 20% - No more than 20% of a hospice bill can be spent on high-acuity care. VITAS retention spend during labor crunch: $37 million - Spent on retention bonuses for nurses during high inflation and staffing shortages. VITAS recruiting spend during labor crunch: $3 million - Additional spend to recruit nurses. VITAS acquisition: $85 million - Recent acquisition mentioned as an exception to mostly organic growth. KemEd free cash flow since 2004: ~$3.7 billion - Cash generated after capex over the holding period. Capital expenditures since 2004: $600 million to $700 million - Approximate reinvestment level during the period. Acquisition spend since 2004: ~$700 million - Cumulative M&A spending across the portfolio. Dividends paid since 2004: ~$300 million - Modest but growing dividend policy. Share repurchases since 2004: ~$2.5 billion - Major use of free cash flow for buybacks. Share count reduction: From ~25 million to ~15 million shares - Illustrates meaningful share cannibalization. General manager attrition to private equity: ~20% in 2021 - Competitive pressure on Roto-Rooter’s talent base. Private equity managers returning: About half within 1.5 to 2 years - Suggests KemEd’s platform remained attractive relative to PE alternatives.

Pivotal Quotes: "Our business is to grow our free cash flow per share, and we're agnostic on how we do it." — Chad Garcia: Summarizing KemEd management’s philosophy and what the company exists to optimize. "Old people, old houses." — Chad Garcia: A shorthand description of KemEd’s two very different but durable end markets. "They said, our business is to grow our free cash flow per share, and we're agnostic on how we do it." — Chad Garcia: Reinforcing the company’s capital allocation mindset as the central thesis.

Implications: KemEd shows how boring, fragmented, asset-light businesses can create exceptional value when paired with disciplined capital allocation. The lesson: durable cash flows, buybacks, and opportunistic ownership changes can compound faster than flashy growth.